Prevo-Check®
Early detection of HPV-induced precancerous lesions (e.g., CIN2+)
Key Facts
About Abviris
Abviris, founded in 2018 and based in Berlin, is a private diagnostics company focused on transforming HPV-related cancer screening through serology. Its core technology enables the detection of specific antibody biomarkers from a simple blood draw, with its flagship product, Prevo-Check®, designed for early detection of precancerous lesions and monitoring after treatment. The company is pre-revenue and in the development/commercialization stage, having recently secured nearly €2 million in funding to expand its biomarker platform. Abviris represents a novel approach in a large, established screening market dominated by molecular and cytology tests.
View full company profileAbout Abviris
Abviris, founded in 2018 and based in Berlin, is a private diagnostics company focused on transforming HPV-related cancer screening through serology. Its core technology enables the detection of specific antibody biomarkers from a simple blood draw, with its flagship product, Prevo-Check®, designed for early detection of precancerous lesions and monitoring after treatment. The company is pre-revenue and in the development/commercialization stage, having recently secured nearly €2 million in funding to expand its biomarker platform. Abviris represents a novel approach in a large, established screening market dominated by molecular and cytology tests.
View full company profile